Continuation of adjuvant capecitabine treatment in TNBC patients and ado-trastuzumab emtansine (T-DM1) in HER2+ BC patients (in case of residual disease in post-neoadjuvant setting) [25,28];. Here, ERBB2 is linked to breast cancer.